Feedback PLC (FDBK.L) People | Reuters.com
Edition:
United States

Feedback PLC (FDBK.L)

FDBK.L on London Stock Exchange

1.00GBp
24 Jun 2016
Change (% chg)

0.00p (+0.00%)
Prev Close
1.00p
Open
1.00p
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
178,387
52-wk High
3.50p
52-wk Low
0.57p

Summary

Name Age Since Current Position

Thomas Charlton

57 2016 Deputy Chairman of the Board

Alastair Riddell

66 2016 Non-Executive Chairman of the Board

Mark Bird

2011 Director - Sales, Executive Director

Balaji Ganeshan

33 2015 Director

Michael Hayball

48 2015 Director

Alexander Menys

29 2015 Director

Simon Barrell

56 2012 Non-Executive Director

Trevor Brown

68 2014 Non-Executive Director

Biographies

Name Description

Thomas Charlton

Mr. Thomas William George Charlton is no longer Deputy Chairman of the Board of the Company, effective November 2016. He previously served as a director of Feedback plc between January 2003 and November 2004 and has been a significant shareholder in the company since December 1997. He acted as chairman of Pinnacle Staffing Group plc from September 2008 until April 2011. Earlier in his career he was a managing director of Merrill Lynch Investment Managers and a director of Mercury Asset Management Limited.

Alastair Riddell

Dr. Alastair James Riddell is the Non-Executive Chairman of the Board of the Company. He has over 30 years' experience in the pharmaceutical, life science and biotech industries, with 18 years as a main board director. After 10 years directing phases 1-4 clinical trials of antibiotics, oncology and intensive care products for companies including Lederle (now Pfizer) and Centocor (now J&J), he spent five years managing sales and marketing for oncology and imaging products for Amersham International (now GE Healthcare). This led to 12 years as CEO for three UK biotech companies, Pharmagene, Paradigm Therapeutics and Stem Cell Sciences; in these roles he was the principal involved in an IPO on UK's main list, trade sales to international companies in Japan and the USA and significant fund raising rounds. He has been Chairman of Silence Therapeutics (AIM listed) and Chairman of Definigen Ltd, a private Cambridge University spinout. He is currently on the Board of three biotechnology companies; AzurRx Biotherapeutics, a private New York based drug development company; Cristal Therapeutics, a Netherlands based company specialising in nanoparticle medicines; and Skyline Vet Pharma, a US based private company repurposing human drugs for use in companion animals. He is also Chairman of the SWAHSN (South West Academic Health Science Network), which seeks to improve and sustain the healthcare provision in the south-west of England by linking innovation from industry, academia and the NHS.

Mark Bird

Mr. Mark Peter Bird is Director - Sales, Executive Director of Feedback Plc. Prior to this he was a founding director of a software start-up and he has previously held board positions as either sales or managing director in a number of companies including Steljes Ltd which operates in the education sector.

Balaji Ganeshan

Dr. Balaji Ganeshan is Director of the Company. He holds or has held the following directorships and/or partnerships in the previous five years are TexRad Limited, Cambridge Computed Imaging Limited, Stone Checker Software Ltd, Prostate Checker Ltd.

Michael Hayball

Mr. Michael Peter Hayball is Director of the company. He holds or has held the following directorships and/or partnerships in the previous five years are - Cambridge Computed Imaging Limited, TexRad Limited.

Alexander Menys

Dr. Alexander Henry Menys is Director of the Company. He holds or has held the following directorships and/or partnerships in the previous five years : Motilent Limited.

Simon Barrell

Mr. Simon Gregory Barrell has been appointed as Non-Executive Director of Feedback Plc., effective November 12, 2012. He is qualified as a chartered accountant with Arthur Young in 1983. He then joined an accountancy practice in Nairobi, Kenya as a Senior Manager. On his return to the UK in 1987, he joined Binder Hamlyn. In 1994 Simon was appointed finance director of Napier Brown & Company Limited and subsequently was appointed finance director of Napier Brown Foods Plc in December 2003. Since leaving Napier Brown & Company Plc in 2005 Simon has been finance director in an executive and non-executive capacity for a number of public companies and continues to act as an adviser to listed and non-listed companies. He has also been appointed as the member of Audit and Remuneration Committees. He also serves as a Director of SureTrack Monitoring plc, Phoenix Opportunities Limited, IBP Limited, Healthcare Holdings plc, Matisse Holdings plc.

Trevor Brown

Mr. Trevor Edward Brown is Non-Executive Director of the Company. He has been a strategic investor in real estate and equities for more than 30 years. He was most recently a director of Advanced Oncotherapy plc where he was involved in the strategy of transition to the provision of advanced cancer treatment services.

Basic Compensation